Advancing clinical-basic-clinical research: exploring novel immunotargets for ovarian cancer  

作　　者：Yuanzhuo Gu Long Zhang Weiguo Lv 

机构地区：[1]Department of Gynecological Oncology,Women’s Hospital,Zhejiang University School of Medicine,310006,Hangzhou,China [2]MOE Key Laboratory of Biosystems Homeostasis&Protection and Innovation Center for Cell Signaling Network,Life Sciences Institute,Zhejiang University,310058,Hangzhou,China

出　　处：《Signal Transduction and Targeted Therapy》2024年第10期4172-4174,共3页信号转导与靶向治疗（英文）

基　　金：Chinese National Natural Science Funds(31925013,U20A20393,W2411011,82403247);National Key R&D Program of China(2021YFA1101000).

摘　　要：In a recent paper published in Cell,1 Luo and colleagues performed a multi-omics analysis of a prospective phase Ⅱ clinical trial and elucidated the effector regulatory T cells(eTregs)as novel immunotarget for ovarian cancer with homologous recombination deficiency(HRD),analyzing for the first time at the clinical level how poly(ADP-ribose)polymerase(PARP)inhibitors reshape the ovarian cancer microenvironment.The implications of targeting eTregs and combining PARP inhibitors could pave the way for more effective therapies clinically,which is also a typical example of practicing the concept of reverse transformation medicine(RTM)(Fig.1).

关 键 词：CLINICAL cancer IMMUNO 

分 类 号：R737.31[医药卫生—肿瘤]